--- title: 'Industry Daily Summary: What Happened on November 5, 2026' headline: Boehringer’s six-program cancer deal includes $358 million upfront description: Evommune licensed Hinova’s oral autoimmune candidate EVO570, while Boehringer expanded its cardiovascular collaboration with Variant Bio. url: https://thebench.bio/news/industry/2026-11-05 topic: industry date: '2026-11-05' covers: - '2026-11-05' date_published: '2026-11-05T12:10:59Z' date_modified: '2026-11-05T12:10:59Z' tags: - Industry - Research - Software sources: 6 publisher: TheBench.Bio --- # Industry Daily Summary: What Happened on November 5, 2026 **Boehringer’s six-program cancer deal includes $358 million upfront** Evommune licensed Hinova’s oral autoimmune candidate EVO570, while Boehringer expanded its cardiovascular collaboration with Variant Bio. ## Today in brief Boehringer Ingelheim struck a deal with Sino Biopharmaceutical for six preclinical cancer programs, with up to $7 billion in potential milestone payments. [1] [2] Sino will receive $358 million upfront and in near-term payments, and Boehringer may seek rights after clinical milestones. [1] [2] Evommune obtained exclusive rights outside Greater China to Hinova’s autoimmune candidate EVO570 in a deal valued at up to about $1.1 billion. [3] The oral drug is slated for Phase I testing, and Evommune plans a Phase II rheumatoid arthritis trial in 2027. [3] ## Boehringer’s six-program deal could reach $7 billion Boehringer Ingelheim agreed with Sino Biopharmaceutical to license six preclinical oncology programs based on antibody-drug conjugates and T-cell engagers, which direct cancer-killing activity toward tumors. [1] [2] Sino will receive $358 million upfront and in near-term payments, with up to $7 billion more tied to clinical, regulatory, and commercial milestones. [1] [2] Sino may also receive tiered royalties on sales, described as reaching double digits. [1] [4] LaNova Medicines supplied five programs, and Beijing Tide Pharmaceutical supplied one. [2] [5] Sino will lead early development, while Boehringer may take exclusive development, manufacturing, and commercialization rights after specified clinical milestones. [2] [5] Potential rights for four programs exclude mainland China, Hong Kong, and Macau. Rights for the other two may be worldwide. [1] [2] Boehringer opened a research and development center in Shanghai on October 12 to expand local early clinical development and connect Chinese research with its global drug development work. [1] ## Evommune licenses Hinova’s oral autoimmune candidate Evommune licensed exclusive rights outside Greater China to develop, manufacture, and commercialize Hinova’s EVO570, an oral molecular glue degrader designed to disrupt VAV1 signaling. [3] The deal is valued at up to about $1.1 billion and includes $30 million upfront, split between $20 million in cash and $10 million in pre-funded warrants. [3] Hinova may receive development, regulatory, and commercial milestone payments, plus royalties on sales outside Greater China. [3] EVO570, formerly called HC118, has not been approved. A Phase I study is scheduled to assess safety, pharmacokinetics, and target engagement. [3] Evommune chief scientific officer Jeegar Patel said the company plans to report Phase I findings and begin a Phase II rheumatoid arthritis trial in 2027. [3] ## Also worth knowing - Boehringer Ingelheim expanded its collaboration with Variant Bio to cardiovascular disease, raising the agreement’s potential value from an initial $120 million to more than $250 million. [6] ## The day in numbers - **$358 million**: Upfront and near-term payments to Sino Biopharmaceutical for six preclinical oncology programs. [1] [2] - **Up to $7 billion**: Potential milestone payments in Boehringer’s deal, contingent on programs reaching specified benchmarks. [1] [2] - **$30 million**: Evommune’s upfront payment for EVO570 rights, including cash and pre-funded warrants. [3] - **Up to about $1.1 billion**: Potential total value of Evommune’s license deal with Hinova. [3] ## Also published - [PMi Awards 2026: innovation, connection and a changing industry](), pharmaphorum - [ACT Brief: Capturing Trial Friction, AI Matching Model Comparisons, and Boehringer’s Oncology Deal](), Applied Clinical Trials - [PharmatrophiX and Circular partner on neurodegenerative drugs](), Pharmaceutical Technology - [1 in 5 have had multiple biopharma layoffs, poll finds](), BioSpace - [Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie](), Pharmaceutical Executive - [Boehringer forges $7bn alliance with China's SBP Group](), pharmaphorum - [Roundup: Boehringer Ingelheim Licenses Six Oncology Programs From Sino Biopharmaceutical, Nxera Licenses EP4 Agonist to AbbVie](), Pharmaceutical Executive ## Sources 1. [Boehringer secures six Chinese cancer programs in deal worth up to $7B](), European Biotechnology, 2026-11-05 2. [Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion](), BioPharm International, 2026-11-04 3. [Evommune signs $1.1bn licence deal with Hinova for EVO570](), Pharmaceutical Technology, 2026-11-05 4. [The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic](), BioPharm International, 2026-11-04 5. [Boehringer signs oncology deal with Sino Biopharm worth up to $7.4bn](), Pharmaceutical Technology, 2026-11-04 6. [Latest News on TechBio Revolution](), MetaphysicalCells, 2026-11-05 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: [6]: